----item----
version: 1
id: {73526BF3-BE16-4655-A2FB-3B379E66F8A8}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/12/Tetraphase raising $150m
parent: {E53F24E6-BD38-493D-8AAE-66E738CC434C}
name: Tetraphase raising $150m
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 90a88f6b-afd1-4ea8-aff7-95b20ea6f085

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 24

Tetraphase raising $150m
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 24

Tetraphase raising $150m
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1726

<p>Massachusetts-based antibiotic drug developer Tetraphase Pharmaceuticals is aiming to raise $150m through a public offering of 4,300,000 shares of common stock at $35 per share. The offer is expected to close on or around 17 March 2015. Tetraphase reported positive <a href="http://www.scripintelligence.com/researchdevelopment/Tetraphases-antibiotic-as-good-as-Mercks-in-Phase-III-355735" target="_new">Phase III data</a> in December last year for its lead antibiotic compound eravacycline as a treatment for complicated intra-abdominal infections. Data from a second Phase III trial in complicated urinary tract infections are expected by mid-2015. Tetraphase is aiming to file a New Drug Application to the FDA for eravacycline by the end of this year. BMO Capital Markets, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering and Nomura and SunTrust Robinson Humphrey are acting as co-managers.</p><p>For more news and information on antibiotics go to <i>Scrip's</i> dedicate antimicrobial resistance <a href="http://www.scripintelligence.com/amr" target="_new">microsite</a>. </p><p><b>Related articles: </b></p><p><a href="http://www.scripintelligence.com/home/Super-bug-outbreak-spotlights-need-for-potent-antibacterials-356853" target="_new">'Superbug' outbreak spotlights need for potent antibacterials</a> </p><p><a href="http://www.scripintelligence.com/researchdevelopment/Tetraphases-antibiotic-as-good-as-Mercks-in-Phase-III-355735" target="_new">Tetraphase's antibiotic 'as good as Merck's' in Phase III</a></p><p><a href="http://www.scripintelligence.com/home/Who-next-in-antibiotic-MandA-gold-rush-355509" target="_new">Who next in antibiotic M&A gold rush?</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 808

<p>Massachusetts-based antibiotic drug developer Tetraphase Pharmaceuticals is aiming to raise $150m through a public offering of 4,300,000 shares of common stock at $35 per share. The offer is expected to close on or around 17 March 2015. Tetraphase reported positive <a>Phase III data</a> in December last year for its lead antibiotic compound eravacycline as a treatment for complicated intra-abdominal infections. Data from a second Phase III trial in complicated urinary tract infections are expected by mid-2015. Tetraphase is aiming to file a New Drug Application to the FDA for eravacycline by the end of this year. BMO Capital Markets, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering and Nomura and SunTrust Robinson Humphrey are acting as co-managers.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 24

Tetraphase raising $150m
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150312T160002
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150312T160002
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150312T160002
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028088
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 24

Tetraphase raising $150m
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357169
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042309Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

90a88f6b-afd1-4ea8-aff7-95b20ea6f085
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042309Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
